Patent intelligence · US
US 10144930
Inhibitors of MYH7B and uses thereof
Inhibitors of MYH7B and uses thereof
Patent details — US 10144930
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 4, 2018
- Expiration
- Nov 29, 2038
- Applicant
- MIRAGEN THERAPEUTICS, INC.
- Claims
- 24
- CPC classes
- A61K, A61K2300/00, A61K31/7105, A61K31/713
Quick answer
US 10144930 (Inhibitors of MYH7B and uses thereof) is held by MIRAGEN THERAPEUTICS, INC.. Status: granted. Granted Dec 4, 2018. Expires Nov 29, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- MIRAGEN THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 24
- CPC classes
- A61K, A61K2300/00, A61K31/7105, A61K31/713, A61K45/06, A61P
More from MIRAGEN THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 10144930?
US 10144930 (Inhibitors of MYH7B and uses thereof) is held by MIRAGEN THERAPEUTICS, INC.. Status: granted. Granted Dec 4, 2018. Expires Nov 29, 2038 (12 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10144930?
MIRAGEN THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 10144930 expire?
Our index shows an expiration date of Nov 29, 2038 (12 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.